Safety of rituximab therapy during twins' pregnancy
Open Access
- 21 December 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 50 (4) , 806-808
Abstract
Sir, RA affects women more than men and often during childbearing years. Treatment during pregnancy is necessary to control maternal disease in favour of successful pregnancy outcome [1]. Rituximab, a chimeric immunoglobulin G1 (IgG1) monoclonal anti-CD20 antibody depletes circulating B cells and decreases RA activity [2].Keywords
This publication has 12 references indexed in Scilit:
- B lymphocyte cytokines and rheumatic autoimmune diseaseArthritis & Rheumatism, 2009
- Rituximab combined with chemotherapy for lymphoma during pregnancyLeukemia Research, 2009
- Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugsRheumatology, 2008
- The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancyHaematologica, 2007
- Burkitt’s Lymphoma of the Ovary in PregnancyObstetrics & Gynecology, 2006
- Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancyThe Lancet Oncology, 2006
- Administration of rituximab during the first trimester of pregnancy without consequences for the newbornJournal of Perinatology, 2006
- Anti-inflammatory and immunosuppressive drugs and reproductionArthritis Research & Therapy, 2006
- Safety of rituximab therapy during the first trimester of pregnancy: a case historyEuropean Journal of Haematology, 2004
- Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeysTransplant Immunology, 2003